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Objective: This study presents data on the use of continuous glucose
monitoring (CGM) in young children with type 1 diabetes mellitus (T1DM).
CGM provides moment-to-moment tracking of glucose concentrations and
measures of intra- and interday variability, which are particularly salient
measures in young children with T1DM.
Methods: Thirty-one children (mean age = 5.0 yr) with T1DM wore the
Medtronic Minimed CGM for a mean of 66.8 h. The CGM was inserted in
diabetes clinics, and parents were provided brief training.
Results: Few difficulties were experienced and families cited the acceptability
of CGM. Participants’ CGM data are compared with self-monitoring blood
glucose (SMBG) data as well as data from older children with T1DM to
illustrate differences in methodology and variability present in this population.
CGM data are used to calculate glucose variability, which is found to be
related to diabetes variables such as history of hypoglycemic seizures.
Conclusions: CGM is an acceptable research tool for obtaining glucose data
in young children with T1DM and has been used previously in older children
and adults. CGM may be particularly useful in young children who often
experience more glucose variability. Data obtained via CGM are richer and
more detailed than traditional SMBG data and allow for analyses to link
blood glucose with behavior.
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Blood glucose concentrations are an important
measure of health outcomes in type 1 diabetes
mellitus (T1DM) and provide patients with valuable
feedback pertaining to their diabetes management and
relative risk for diabetes-related complications (1–3).
Traditional measures of glucose levels include
hemoglobin A1c (HbA1c) and self-monitored blood
glucose levels. HbA1c provides a measure of the
average glucose concentration over a 2- to 3-month
time period (1). Self-monitored blood glucose (SMBG)
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levels provide patients and health care providers with
real-time snapshots of glucose levels at specific time
points (e.g., before meals, at bedtime).
Continuous glucose monitoring (CGM) is a rela-
tively new technique for measuring glucose levels in
patients with T1DM and has been used for clinical
and research purposes. CGM provides a measure of
glucose concentrations every 5 min, yielding a more
complete picture of glycemic excursion that is free of
bias related to the timing or frequency of testing. CGM
also provides moment-to-moment information about
glucose level variability in contrast to data on mean glu-
cose concentrations (as with HbA1c data) and isolated
observations of glucose levels (as with SMBG data).
Recently, evidence has begun to suggest that glucose
variability is a key factor in the risk for diabetes-related
complications. For example, higher levels of variabil-
ity have been shown to predict increased microvascular
complications in adults with T1DM (4–6). For young
children with T1DM, in particular, glucose variability
is an important consideration. Given the small insulin
doses required for young children, their varying activity
levels, and their often unpredictable eating habits, glu-
cose levels often fluctuate widely on a daily basis despite
parent and health care professionals’ best efforts to
maintain euglycemia (7, 8). CGM provides a method
to more accurately measure glucose variability given
the continuous nature of the data obtained. Although
CGM has been used in clinical care and research with
older children and adolescents with T1DM (9–11), to
date, there have been few studies focusing on glucose
variability in young children with T1DM, and the
use of CGM technology in this population has been
limited (12, 13).
In this brief report, we present data evaluating the
acceptability and benefits of using CGM in a sample
of young children with T1DM and the ways in which
these data may be particularly useful for behavioral
health researchers. In addition, this study seeks to pro-
vide data on the variability of glycemic levels in young
children with T1DM, given that in this population pat-
terns in glucose variability may be more meaningful
to examine than traditional measures of glycemic con-
trol such as HbA1c and SMBG. Finally, we examine
the relations between CGM data and diabetes-related
behavioral variables to provide evidence that contin-
uous glucose data can be linked to more traditional
measures of diabetes care.
Methods
Participants
Participants were 31 children aged 2–7 yr with T1DM
and their caregivers recruited during an outpatient
diabetes clinic visit at two children’s hospitals in the
Midwestern United States in 2006 and 2007. In order
to be eligible for this study, children were required to
be between the ages of 2–7 yr, have been diagnosed
with T1DM for at least 1 yr, and must have used an
insulin pump for diabetes management for a minimum
of 6 months. The mean age of children participating
was 5.0 yr (SD = 1.3), and majority of children were
males (n = 17) and Caucasian (n = 30). Children
participating in this study reported a mean length of
time with diabetes of 2.28 yr (SD = 0.84). Participating
parents were primarily mothers (n = 30); 65% had
obtained a college degree, and socioeconomic status,
based on the Hollingshead Four-Factor Index (14),
was as follows: I (lowest level), 0%; II, 10%; III,
14%; IV, 48%; and IV (highest level), 28%. Out of 47
eligible families approached, 37 agreed to participate.
Parents who declined participation cited scheduling
issues, child anxiety related to CGM use, and concern
about limitations to their child’s activities. Six families
withdrew before initiating the protocol because the
child aged out of the study, the family missed the study
appointment, or because the research team was unable
to reinitiate contact with the family.
Procedure
Data reported are part of a larger investigation of the
relations between child nutrition, behavior, and blood
glucose levels. Institutional Review Board approval
was obtained prior to recruitment. Eligible families
were identified through database review and contacted
via mail with information about the study. Families
were provided with an opt-out postcard to return by
mail if they did not want to be contacted by a member of
the research team. Families who did not return the opt-
out postcard were contacted by phone or at their next
clinic visit to ascertain their interest in study participa-
tion. Families agreeing to participate signed a written
informed consent before completing study activities.
CGM sensor insertion occurred in the diabetes clinic
and was performed by trained study personnel. A top-
ical anesthetic was used if desired by families (EMLA
Cream, Astra Pharmaceuticals, Wayne, PA, USA;
n = 23). During the visit, parents were trained on
the use and calibration of the CGM according to the
guidelines outlined by the manufacturer. The total
time required for an insertion visit averaged 60 min
including parent training. At the end of the monitoring
period, parents could return to clinic to remove the
sensor or remove the sensor at home, and a mem-
ber of the research team picked up the monitor from
the family. Self-monitoring blood glucose (SMBG)
data were downloaded from each child’s blood glucose
(BG) meter. Data were downloaded coinciding with
the CGM monitoring period, and participants had a
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mean of 14 d of SMBG data. CGM data were down-
loaded using the MiniMed Solutions Software version
2.0b (Northridge, CA, USA). Parents were given the
retrospective CGM data upon study completion.
Measures
Minimed Continuous Glucose Monitoring System
Gold®. The CGM is an innovative and relatively non-
invasive device which measures glucose concentrations
over a continuous 72-h period. The sensor is placed just
under the skin using a spring-loaded insertion device,
usually in the abdomen, hip, or buttocks. Glucose
concentrations in the interstitial fluid are measured
every 10 s. Using a computer-driven algorithm, the
sensors relate the subcutaneous interstitial fluid glucose
measurements to capillary BG concentrations, and
the average of these data are stored in the sensor’s
memory every 5 min. The monitor is approximately
9 × 7 × 2 cm, weighs approximately 4 ounces, and
easily clips to clothing or can be placed in a
pocket. A waterproof pouch must be worn over the
monitor during bathing or showering as it cannot
be disconnected without data loss. As this study was
observational in nature, the decision was made to
use a retrospective CGM device rather than a real-
time CGM, which, in providing real-time glucose
information, could have prompted parents to make
changes in their child’s diabetes regimen resulting in an
unintended intervention.
Medical history form. Parents completed a 25-item
questionnaire (15) about weekly diabetes behaviors
such as omitting insulin doses (e.g., ‘how often do you
omit insulin for your child at meals/snack?’), forgetting
insulin boluses (e.g., ‘how many times per week do you
forget to bolus your child at meals/snacks?’), and eating
behaviors (e.g., ‘how many snacks does your child eat
each day?’). Parents responded to each item with an
estimate of how often this behavior ‘typically’ occurred.
This form also contained items about diabetes-related
variables such as duration of T1DM and history of
hypoglycemic seizures.
Glycemic control. Glycemic control was measured
with glycosylated HbA1c, the gold standard assay mea-
suring health status in diabetes care. HbA1c represents
the average BG level over the preceding 8–12 wk, with
higher values indicating poorer glycemic control. Par-
ticipants’ HbA1c value at the time of enrollment or
their most recent prior HbA1c was obtained through
chart reviews. HbA1c tests were processed using the
DCA 2000 at both study sites. Mean HbA1c for par-
ticipants was 7.7% (SD = 0.68), which is within the
American Diabetes Association (ADA) published tar-
get of less than 8.5% for children under age 7 (1).
Results
Glucose data
Overall, participants in the study had a mean of
66.8 h of CGM data (range = 24–79 h). The mean
percent time within range (80–180 mg/dL) for CGM
data for all participants was 44% (SD = 16%, range =
12–74%). Participants’ mean percent time below range
was 5% (SD = 5%, range = 0–19%) and mean percent
time above range was 51% (SD = 17%, range =
20–88%). The mean glucose concentration via CGM
was 191 mg/dL (SD = 39, range = 121–273), whereas
the mean SMBG reading during the monitoring period
was 195 mg/dL (SD = 92, range = 134–273). A paired
sample t-test indicated no difference in mean glucose
obtained via CGM and SMBG. A Pearson correlation
showed a high degree of association between the two
measures, suggesting reliability among the measures
(r = 0.72, p < 0.000). Children’s CGM and SMBG
data are presented in Table 1.
In addition to obtaining mean glucose values,
further calculations were conducted using children’s
CGM data. Each participant’s intraday glycemic vari-
ation was calculated using the continuous overall
net glycemic action (CONGA) statistic (16). CON-
GAn represents the standard deviation of differences
between the current observation and the observa-
tion ‘n’ hours prior (i.e., CONGA1 = 1 h prior;
CONGA2 = 2 h prior; CONGA4 = 4 h prior). The
specific time intervals of 1, 2, and 4 h are used as
these periods are hypothesized to be approximate
times between snacks and meals. Higher CONGAn
values represent more glucose variability, which sug-
gests poorer glycemic control within a 24-h period.
Published reports suggest that adults without T1DM
have mean CONGA1, COGNA2, and CONGA4 val-
ues of 13, 15, and 18 mg/dL, whereas older children
and adolescents with T1DM have values of 44, 64,
and 83, respectively (16). Participants in this study had
mean CONGA1, COGNA2, and CONGA4 values
of 58 (SD = 8), 83 (SD = 11), and 105 mg/dL (SD =
15), respectively (Table 1). We compared previously
reported glucose variability values with our current
data using one-sample t-tests (Table 2). There were sig-
nificant differences in glucose variability between older
children with T1DM (16) and young children with
T1DM in this study based on CONGA1 (t(30) = 8.67,
p < 0.000), CONGA2 (t(30) = 9.05, p < 0.000), and
COGNA4 (t(30) = 7.45, p < 0.000) values. Results
suggested that younger children in this study had more
glucose variability than older children with T1DM.
Children’s interday glycemic variation was calcu-
lated using the mean daily differences (MODD) statis-
tic. MODD is equal to the mean absolute value of the
difference between glucose values taken on two con-
secutive days at the same time. Higher MODD values
Pediatric Diabetes 2010 3
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Table 1. Mean glucose levels, variation, and time in range by participant








SMBG CONGA1 CONGA2 CONGA4 MODD Below range In range Above range
5/M 8.6 268 256 67 97 113 94 0 17 83
6/F 7.5 168 172 50 72 90 74 2 64 34
6/F 8.9 202 213 64 96 123 77 1 47 52
4/M 8.0 235 208 58 90 126 104 2 25 73
6/F 8.7 186 196 46 66 84 68 2 45 53
4/M 7.0 158 192 60 73 100 68 11 57 32
6/F 7.8 212 222 55 85 101 88 0 38 62
5/F 7.7 268 223 74 114 145 79 2 15 82
3/M 8.0 282 270 62 95 107 116 0 10 90
5/M 7.2 213 212 67 91 121 138 13 28 59
6/F 7.4 171 165 52 75 94 72 5 55 40
2/M 8.3 128 134 67 86 100 79 24 52 23
6/M 6.8 182 184 48 69 98 90 9 42 50
7/F 6.6 144 169 44 66 81 35 6 74 20
3/M 7.5 173 166 62 99 126 65 5 58 38
6/M 7.0 187 209 45 68 97 64 0 54 46
6/M 7.5 185 186 56 87 105 93 4 48 48
3/M 8.1 214 188 54 82 106 79 3 37 59
6/F 7.8 181 162 63 82 102 66 7 44 49
6/F 8.3 200 273 54 78 115 118 7 35 59
5/M 9.1 197 179 58 84 107 65 2 40 59
6/F 8.0 150 190 68 94 128 75 19 51 30
4/M 8.9 188 145 53 84 102 108 0 52 48
7/M 6.8 141 178 66 80 85 119 16 58 26
5/F 7.1 169 154 50 69 90 86 3 60 37
5/M 7.5 198 203 62 84 100 89 0 50 50
5/F 7.4 179 177 57 71 79 68 2 50 48
5/M 8.4 249 206 57 84 114 128 3 26 71
5/F 7.5 187 205 69 90 111 119 5 54 42
4/M 7.4 161 200 55 79 95 83 7 51 41
6/F 7.8 208 218 70 97 123 108 9 36 55
HbA1c, hemoglobin A1c; CGM, continuous glucose monitoring; SMBG, self-monitoring blood glucose; CONGA1, continuous
overall net glycemic action (1 h); CONGA2, 2 h; CONGA4, 4 h; MODD, mean daily differences.
Below range = <80 mg/dL; in range = 80–180 mg/dL; above range = >180 mg/dL.
Table 2. Comparison of glucose variability in young children







MODD 88 ± 23∗ 78 ± 27∗
CONGA1 58 ± 8∗∗ 44 ± 8∗∗
CONGA2 83 ± 11∗∗ 64 ± 14∗∗
CONGA4 105 ± 15∗∗ 82 ± 24∗∗
T1DM, type 1 diabetes mellitus; MODD, mean observed
daily difference; CONGA1, continuous overall net glycemic
action (1 h); CONGA2, 2 h; CONGA4, 4 h.
Values shown are mean ± SD. Means in the same row with
asterisks are significantly different at the following levels:
*p = 0.057; **p < 0.000.
may indicate poorer glycemic control across multiple
days and/or a more irregular daily schedule. Table 1
lists MODD statistics for each participant. One-sample
t-tests comparing current MODD scores with MODD
scores reported previously (16) suggested that differ-
ences in interday glucose variability that approached
significance (t(30) = 2.00, p = 0.057). Younger chil-
dren with T1DM were found to have greater interday
variability in their glucose levels than adolescents with
T1DM (Table 2).
Relation between CGM and diabetes-related
variables
Final analyses examined the relationship between
CGM statistics (average CGM value, MODD,
and CONGAn) and the diabetes-related adherence
variables: number of omitted insulin dosages at meals
or snacks per week, daily blood glucose monitoring
frequency, and number of meals or snacks per day.
Pearson r correlations were used for these analyses.
Results suggested a significant negative correlation
between average CGM value and parent report of
omitted insulin dosages at meals/snacks (r = −0.371,
p < 0.04). Mean CGM value was positively correlated
with HbA1c (r = 0.387, p < 0.03) but mean SMBG
was not. Other relationships were not significant.
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Additionally, t-tests were conducted to determine
differences in CGM statistics based on the parent
report of child experiencing a hypoglycemic seizure
(yes vs. no). Children who had experienced at
least one hypoglycemic seizure (n = 8) had higher
CONGA2 values (mean = 91.7) than those who had
not experienced a seizure (mean = 81.5, t(28) = 2.0,
p < 0.05). Children who had experienced at least one
hypoglycemic seizure also had higher CONGA4 values
(mean = 118.4) than those who had not experienced a
seizure (mean = 101.7, t(28) = 2.5, p < 0.04).
Discussion
This study provides information regarding the type of
data that can be obtained using CGM technology in
young children with T1DM. In particular, the use of
calculations for intra- and interdaily variations, such
as CONGA and MODD, can provide a more complete
and accurate picture of participants’ glucose levels than
traditional measures of glycemic control. Participants
in this study had greater glucose variability, as assessed
by CONGAn and MODD, than adults without T1DM
and older children and adolescents with T1DM, as
would be expected given the challenges of maintaining
euglycemia in young children with this condition. This
finding supports the assertion that young children are
more likely to experience extreme glucose variability.
This is likely because of a number of factors
including heightened insulin sensitivity, fluctuating
activity levels, and erratic eating behaviors (7, 8), and
this may place these young children at increased risk
for diabetes-related complications in the future (4–6).
It also suggests that glucose variability may be an
important measure of glycemic control to study in this
young population and target through intervention.
In this study, we were also able to link measures
of glycemic control and variability with diabetes-
related variables. Our results suggest that children
with a history of hypoglycemic seizures have increased
glycemic variability, and this finding echoes results
found in older individuals with T1DM (4). This may
indicate these children have generally more fluctuating
glucose levels, making seizures more likely. We also
found that higher frequency of omitted meal boluses
was related to lower mean CGM values. This finding
may be explained by parents of children, with typically
lower glucose levels, more frequently omitting the
meal or snack insulin bolus because of hypoglycemia.
Interestingly, our data show a relation between HbA1c
and mean CGM values but not with SMBG values.
This finding supports the assertion that the use of
SMBG data as a proxy for glycemic control may
be ineffective. Given that SMBG data are highly
dependent on the frequency and timing of BG checks
(e.g., before meals, when they believe the child has a
high or low glucose), it may not provide an accurate
representation of overall glycemic control. Overall,
our results suggest that using CGM technology and
the calculation of glycemic variability statistics can
provide a richer, more accurate picture of young
children’s glucose levels. In contrast, SMBG data may
not link with glycemic control in this population, and
the singular use of HbA1c values may mask important
patterns in glucose variability which could impact
overall glucose levels.
In addition to these benefits, there are a number of
potentially exciting and novel uses of CGM data for
behavioral researchers. For example, intradaily mea-
surement can provide useful data about how often
or rapidly glucose levels are changing. In the future,
researchers may be able to link daily variability to con-
structs such as neurocognitive functioning, behavior,
mood, or even diabetes-specific factors such as fear
of hypoglycemia. Interdaily measurement of glucose
variability provides researchers with the potential to
document the impact of interventions targeting glucose
control at a more refined level rather than only docu-
menting mean change in glucose levels (i.e., HbA1c).
For instance, researchers may be able to track how
adherence to behavioral interventions impacts glucose
variability on a day-to-day basis and if the interven-
tions can lead to more stable improvements in glucose
variability. Furthermore, CGM data can be used to
test relations between psychological or behavioral con-
structs with specific time periods of interest, such as
postprandial glucose levels, overnight glucose levels,
or the frequency of undetected hypoglycemic events.
In older children, researchers have begun to examine
the relations between child mood, behavior, and CGM
data. McDonnell et al. (17) used CGM technology in
school-age children with T1DM. These researchers
found that higher frequencies of externalizing behav-
ior were related to greater length of time above the
target glucose range. To our knowledge, this is the
only study that has examined the link between behav-
ior and CGM data in children, and thus the potential
for future work in this area is great.
This study also demonstrates the feasibility of using
CGM in young children with T1DM. Anecdotally,
families in this study were excited about participation
and frequently cited the benefit of the retrospective
CGM data in terms of improving their child’s
diabetes care. Two families in the study experienced
insertion difficulties; however, each opted to undergo
a second insertion on the same day. Although the
manufacturer’s instructions report that mild irritation
at the insertion site is possible, participants in this study
did not experience this or other adverse events.
Despite the wealth of data provided by CGM,
there are obstacles to widespread use in research. In
this study, some participants displayed anticipatory
Pediatric Diabetes 2010 5
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anxiety about the insertion which could hinder research
participation. Additionally, CGM is vulnerable to
malfunctions and misuse. Eight families experienced
minor difficulties including two insertion problems,
one sensor failure, one CGM monitor failure, and
four parent mismanagement issues (e.g., parents
not entering SMBG data required for calibration).
Depending on the type of difficulty encountered, some
loss of data may occur. Based on our experience,
we recommend planning for 5–10% more participants
than needed in order to account for unexpected data
loss. Finally, although CGM has been used successfully
in this study and two other research protocols (17,
18), it is not currently approved by the Food and
Drug Administration for use in children under 7
yr old, which may create an obstacle when seeking
institutional approval for research.
There are several limitations of this study. Although
it is notable that associations were found despite the
small sample size, additional participants could provide
increased power to detect other associations of inter-
est. This study only recruited children using an insulin
pump. Thus, the ability to generalize the results to a
conventionally managed population may be limited. In
addition, it would be useful for future studies to incor-
porate objective measures of diabetes management
behaviors (e.g., insulin omission, carbohydrate intake)
which could be linked with CGM data. Finally, in
this study, families did not provide standardized feed-
back about their experience with the CGM technology.
Therefore, feasibility data presented are anecdotal. It
would be useful for future work to incorporate stan-
dardized measures of acceptability and satisfaction to
more objectively measure this construct.
To conclude, CGM provides detailed, objective data
about glucose concentrations and trends, and the use
of this technology is feasible, even for young children
with T1DM. Although more traditional measures of
glycemic levels, such as SMBG, provide data at dis-
crete time points which may be predisposed to extreme
values (e.g., premeal glucose or when hypo- or hyper-
glycemia is suspected), CGM data provide an unbiased
sample of glucose values. Moreover, CGM is the only
device available that can directly measure glycemic
variability, and the percent of time participants is at
specific glycemic concentrations. These types of mea-
surements can be particularly useful for behavioral
researchers examining associations between patients’
psychosocial functioning, self-care behaviors, and their
glycemic control. These data may also become the
best way to assess for glucose variability, which evi-
dence suggests should be a target for future behavioral
interventions (4–6). Overall, CGM provides a tech-
nologically advanced method of obtaining data that
allows for a richer and more detailed examination of
glucose trends and correlates in children with T1DM.
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